

Cameron J Turtle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4656410/publications.pdf>

Version: 2024-02-01

72
papers

12,306
citations

87723

38
h-index

110170

64
g-index

75
all docs

75
docs citations

75
times ranked

11966
citing authors

#	ARTICLE	IF	CITATIONS
1	ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 625-638.	2.0	1,741
2	CD19 CAR ⁺ T cells of defined CD4 ⁺ :CD8 ⁺ composition in adult B cell ALL patients. <i>Journal of Clinical Investigation</i> , 2016, 126, 2123-2138.	3.9	1,657
3	Endothelial Activation and Blood ⁺ Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. <i>Cancer Discovery</i> , 2017, 7, 1404-1419.	7.7	945
4	Immunotherapy of non-Hodgkin ⁺ lymphoma with a defined ratio of CD8 ⁺ and CD4 ⁺ CD19-specific chimeric antigen receptor ⁺ modified T cells. <i>Science Translational Medicine</i> , 2016, 8, 355ra116.	5.8	832
5	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor ⁺ modified T-cell therapy. <i>Blood</i> , 2017, 130, 2295-2306.	0.6	774
6	Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1233-1244.	5.2	661
7	Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> , 2016, 127, 2406-2410.	0.6	622
8	Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor ⁺ Modified T Cells After Failure of Ibrutinib. <i>Journal of Clinical Oncology</i> , 2017, 35, 3010-3020.	0.8	568
9	Overlap and Effective Size of the Human CD8 ⁺ T Cell Receptor Repertoire. <i>Science Translational Medicine</i> , 2010, 2, 47ra64.	5.8	374
10	Infectious complications of CD19-targeted chimeric antigen receptor ⁺ modified T-cell immunotherapy. <i>Blood</i> , 2018, 131, 121-130.	0.6	374
11	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , 2019, 133, 1652-1663.	0.6	277
12	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , 2019, 133, 1876-1887.	0.6	230
13	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 26-33.	2.0	222
14	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , 2020, 135, 1650-1660.	0.6	222
15	Chimeric Antigen Receptor T Cell ⁺ Mediated Neurotoxicity in Nonhuman Primates. <i>Cancer Discovery</i> , 2018, 8, 750-763.	7.7	184
16	Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. <i>CNS Drugs</i> , 2018, 32, 1091-1101.	2.7	175
17	A Distinct Subset of Self-Renewing Human Memory CD8 ⁺ T Cells Survives Cytotoxic Chemotherapy. <i>Immunity</i> , 2009, 31, 834-844.	6.6	163
18	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138

#	ARTICLE	IF	CITATIONS
19	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , 2019, 134, 636-640.	0.6	127
20	Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. <i>Drugs</i> , 2017, 77, 237-245.	4.9	112
21	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021, 137, 323-335.	0.6	111
22	Cytokines in CAR T Cell-Associated Neurotoxicity. <i>Frontiers in Immunology</i> , 2020, 11, 577027.	2.2	110
23	Toxicities of CD19 CAR-T cell immunotherapy. <i>American Journal of Hematology</i> , 2019, 94, S42-S49.	2.0	102
24	Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. <i>Current Research in Translational Medicine</i> , 2018, 66, 50-52.	1.2	100
25	Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 705-716.	2.0	93
26	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 34-43.	2.0	93
27	Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. <i>American Journal of Hematology</i> , 2019, 94, E209-E213.	2.0	92
28	Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma. <i>Blood</i> , 2018, 132, 1011-1011.	0.6	91
29	Artificial Antigen-Presenting Cells for Use in Adoptive Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq1 1 0.784314 rgBT /Over	1.0	79
30	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	2.5	74
31	Graft-Derived Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 242-251.	2.0	70
32	Engineered T cells for anti-cancer therapy. <i>Current Opinion in Immunology</i> , 2012, 24, 633-639.	2.4	68
33	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , 2020, 55, 1706-1715.	1.3	66
34	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2055-2068.	2.5	60
35	Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. <i>Bone Marrow Transplantation</i> , 2019, 54, 780-784.	1.3	52
36	Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. <i>Blood Advances</i> , 2019, 3, 3590-3601.	2.5	52

#	ARTICLE	IF	CITATIONS
37	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	0.6	52
38	Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?. <i>Blood</i> , 2020, 136, 137-139.	0.6	51
39	Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes. <i>Blood</i> , 2015, 126, 184-184.	0.6	49
40	Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity. <i>Journal of Immunology</i> , 2019, 202, 476-483.	0.4	41
41	Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 653-664.	1.4	39
42	Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 3773-3773.	0.6	39
43	Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2011, 23, 299-305.	2.4	35
44	Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. <i>Journal of Medical Virology</i> , 2021, 93, 2270-2280.	2.5	32
45	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. <i>Journal of Critical Care</i> , 2020, 58, 58-64.	1.0	31
46	CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success. <i>BioDrugs</i> , 2021, 35, 281-302.	2.2	30
47	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. <i>Blood</i> , 2022, 139, 3722-3731.	0.6	28
48	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020, 4, 3239-3245.	2.5	19
49	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. <i>JCI Insight</i> , 2021, 6, .	2.3	18
50	CMRF-56 ⁺ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. <i>Oncolmmunology</i> , 2016, 5, e1168555.	2.1	17
51	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 4869-4872.	2.5	12
52	CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 56-56.	0.6	11
53	Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study. , 2021, 9, e003428.		11
54	Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies. <i>Future Oncology</i> , 2021, 17, 3549-3560.	1.1	10

#	ARTICLE	IF	CITATIONS
55	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. <i>Blood</i> , 2018, 132, 94-94.	0.6	10
56	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. <i>Blood</i> , 2021, 138, 429-429.	0.6	9
57	Neurotoxicities After CAR T-Cell Immunotherapy. , 2020, , 83-105.		7
58	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. <i>Blood</i> , 2021, 138, 3872-3872.	0.6	7
59	Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 38-39.	0.6	7
60	Combination of NKTR-255, a Polymer Conjugated Human IL-15, with CD19 CAR T Cell Immunotherapy in a Preclinical Lymphoma Model. <i>Blood</i> , 2019, 134, 2866-2866.	0.6	6
61	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. <i>Blood</i> , 2020, 136, 37-38.	0.6	6
62	CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. <i>Immunotherapy</i> , 2018, 10, 251-254.	1.0	5
63	Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 98-106.	1.0	2
64	Generation of CD8+ Cytotoxic T Cell Clones Recognizing BMI1-Derived Peptides. <i>Blood</i> , 2008, 112, 2909-2909.	0.6	2
65	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 1-2.	0.6	2
66	Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry. <i>Journal of Immunological Methods</i> , 2021, 492, 112955.	0.6	1
67	Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Blood</i> , 2019, 134, 4453-4453.	0.6	1
68	Toxicities of CD19-targeted CAR-T cell therapy. <i>Pathology</i> , 2018, 50, S39-S40.	0.3	0
69	Chemotherapy-Resistant T Cells. <i>Blood</i> , 2010, 116, SCI-51-SCI-51.	0.6	0
70	Generation and Signaling Function of CD19 Chimeric Antigen Receptor Modified CD8+ T Cells Derived From Virus-Specific Central Memory Cells for Adoptive Therapy After Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2011, 118, 2978-2978.	0.6	0
71	Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy. <i>Blood</i> , 2021, 138, 2776-2776.	0.6	0
72	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 0, , 1-5.	0.6	0